At the European Hematology Association 2026 Congress, Legend Biotech CEO Dr. Ying Huang discussed the promising early results of LB2501, their investigational in vivo CAR T-cell therapy targeting both CD19 and CD20 for hematologic cancers. The Phase 1 study showed a 100% response rate and complete responses in five out of six patients at a specific dosage, suggesting potential efficacy against relapsed or refractory lymphoma. Dr. Huang highlighted the challenges of relapse associated with existing CD19 therapies, advocating for the dual-targeting approach to reduce cancer cell resistance. Legend Biotech plans to file an investigational new drug application to further develop LB2501 in the U.S.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://oncodaily.com/oncolibrary/legend-biotech-lb2501-eha
